One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
ﻗﯿﻤﺖ : 300$- ﻗﯿﻤﺖ ﻭﯾﮋﻩ : 100$
Novel light on the many facets of myocardial revascularization: optical coherence tomography for calcified lesions, physiological stenosis assessment, residual risk assessment, preventive percutaneous coronary intervention, and preventive pericardiotomy
doi : 10.1093/eurheartj/ehaf527
Volume 46, Issue 32, 21 August 2025
Innovative artificial intelligence for practice management in medical healthcare
CardioMetabolic medicine: the advent of systems cardiology and the new cardiovascular generalist?
Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence
Great debate: transcatheter aortic valve implantation should also be performed in non-surgical centres
Residual cholesterol and inflammatory risk in statin-treated patients undergoing percutaneous coronary intervention
Residual cardiovascular risk beyond low-density lipoprotein cholesterol: inflammation, remnant cholesterol, and lipoprotein(a)
Preventive percutaneous coronary intervention for non-flow-limiting vulnerable atherosclerotic coronary plaques in diabetes: the PREVENT trial
Preventive stenting of vulnerable plaques in diabetic patients: is it worth it?
Optical coherence tomography- vs angiography-guided coronary stent implantation in calcified lesions: the ILUMIEN IV trial
Mastering percutaneous coronary intervention in calcified coronary lesions with optical coherence tomography: the path to optimal outcomes
Coronary artery bypass grafting with or without preoperative physiological stenosis assessment: a SWEDEHEART study
Physiological stenosis assessment for coronary artery surgery: quo vadis?
Posterior left pericardiotomy in cardiac surgery and outcomes: PALACS-EF trial extended follow-up
Electrical storm and refractory heart failure necessitating left ventricular assist device in ischaemic cardiomyopathy with apical aneurysm
Weekly Journal Scan: Extending anticoagulation beyond 6 months after venous thromboembolism in patients with active cancer. Is low-dose apixaban the answer?
Correction to: Individual patient data meta-analysis of paclitaxel-coated balloons vs. drug-eluting stents for small-vessel coronary artery disease: the ANDROMEDA study
